CDMO Avid Bioservices

Avid Bioservices to Participate at Upcoming Investor Conferences

Avid Bioservices to Participate at Upcoming Investor Conferences

TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate at two upcoming investor conferences. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference, and will deliver a corporate presentation at the 2024 Bank of America Securities Healthcare Conference.

Details of the company’s participation are as follows:

  • RBC Capital Markets 2024 Global Healthcare Conference

    Conference Date: May 14-15, 2024

    Fireside Chat Time/Date: 4:35 – 5:05 p.m. Eastern on Tuesday, May 14, 2024

    Location: InterContinental New York Barclay, New York
  • 2024 Bank of America Healthcare Conference

    Conference Date: May 14-16, 2024

    Presentation Time/Date: 11:55 a.m. – 12:10 p.m. Eastern on Thursday, May 16, 2024

    Location: Encore Hotel, Las Vegas, NV

About Avid Bioservices, Inc. 

Avid Bioservices (NASDAQ: CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. 



Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
 

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
EN
07/05/2024

Underlying

CDMOAvid Bioservices

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avid Bioservices

 PRESS RELEASE
Free
CDMO Avid Bioservice...

Avid Bioservices to Participate at Upcoming Investor Conferences

Avid Bioservices to Participate at Upcoming Investor Conferences TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate at two upcoming investor conferences. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the RBC Capital Markets 20...

May 7, 2024 1 EN
 PRESS RELEASE
Free
CDMO Avid Bioservice...

Avid Bioservices Reports Financial Results for Third Quarter Ended Jan...

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 -- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion Program with Grand Opening of Cell and Gene Therapy Manufacturing Facility in January 2024 -- -- Completed Convertible Debt Offering Subsequent to Quarter End, Extending Debt Maturity to 2029 -- TUSTIN, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contra...

April 24, 2024 1 EN
 PRESS RELEASE
Free
CDMO Avid Bioservice...

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Re...

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the “Notice”) on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to ...

March 20, 2024 1 EN
 PRESS RELEASE
Free
CDMO Avid Bioservice...

Avid Bioservices Announces Pricing of Private Placement of Convertible...

Avid Bioservices Announces Pricing of Private Placement of Convertible Notes TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029 Notes”). In connection with the offering, the company entered into private placement purchase agreements with the several purchasers, each of whom is a “qualified institutional buyer” within the meaning of Rule 144A promul...

March 7, 2024 1 EN
 PRESS RELEASE
Free
CDMO Avid Bioservice...

Avid Bioservices Announces Proposed Private Placement of Convertible N...

Avid Bioservices Announces Proposed Private Placement of Convertible Notes TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 (the “2029 Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Section 4(a)(2) of the Securities Act of 19...

March 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch